Boston Scientific Corporation $BSX Shares Acquired by Hobart Private Capital LLC

Hobart Private Capital LLC grew its position in Boston Scientific Corporation (NYSE:BSX) by 128.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,295 shares of the medical equipment provider’s stock after purchasing an additional 2,979 shares during the period. Hobart Private Capital LLC’s holdings in Boston Scientific were worth $569,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Sumitomo Mitsui Trust Group Inc. grew its holdings in Boston Scientific by 2.4% during the second quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,579,659 shares of the medical equipment provider’s stock worth $384,491,000 after acquiring an additional 84,529 shares during the period. GLOBALT Investments LLC GA grew its holdings in Boston Scientific by 8.8% during the second quarter. GLOBALT Investments LLC GA now owns 9,322 shares of the medical equipment provider’s stock worth $1,001,000 after acquiring an additional 754 shares during the period. Catalyst Capital Advisors LLC grew its holdings in Boston Scientific by 43.5% during the second quarter. Catalyst Capital Advisors LLC now owns 2,267 shares of the medical equipment provider’s stock worth $243,000 after acquiring an additional 687 shares during the period. Asset Management One Co. Ltd. grew its holdings in Boston Scientific by 4.5% during the second quarter. Asset Management One Co. Ltd. now owns 768,034 shares of the medical equipment provider’s stock worth $82,495,000 after acquiring an additional 32,834 shares during the period. Finally, R Squared Ltd grew its holdings in Boston Scientific by 103.9% during the second quarter. R Squared Ltd now owns 15,356 shares of the medical equipment provider’s stock worth $1,649,000 after acquiring an additional 7,826 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $18,659,923.46. This trade represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,469,268. The trade was a 42.32% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 170,214 shares of company stock worth $17,548,337. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Stock Performance

NYSE BSX opened at $101.08 on Friday. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50. The company has a market cap of $149.78 billion, a PE ratio of 54.06, a price-to-earnings-growth ratio of 2.37 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The stock’s 50 day simple moving average is $101.14 and its 200-day simple moving average is $102.00.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The firm had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. During the same quarter last year, the business posted $0.63 earnings per share. The firm’s revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analysts Set New Price Targets

BSX has been the topic of several analyst reports. Raymond James Financial raised their target price on Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a report on Thursday, July 24th. Wall Street Zen raised Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 11th. Robert W. Baird raised their price objective on Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, October 1st. Truist Financial raised their price objective on Boston Scientific from $129.00 to $130.00 and gave the company a “buy” rating in a report on Thursday. Finally, The Goldman Sachs Group reissued a “buy” rating and issued a $124.00 price objective on shares of Boston Scientific in a report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $123.77.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.